A Site-Specific B7-H3 Targeting Antibody-Drug Conjugate for Cancer Therapy
Автор: 經濟部產業技術司 · 解密科技寶藏
Загружено: 2024-12-10
Просмотров: 51
Описание:
The project was adapted DCB owned proprietary trimannose-based conjugation technology to develop a site-specific and homogeneous B7-H3 targeting ADC candidate DCBAD2303. DCBAD2303 exhibits high affinity, specificity, selective cytotoxicity to tumor cells, high antitumor efficacy in the large or small tumor mice model, good pharmacokinetic profile and preclinical safety in vivo. DCBAD2303 has high potential for treating B7-H3-positive tumors such as HNSCC and prostate cancer.
#經濟部產業技術司 #科技專案 #創新領航館 #解密科技寶藏
#台灣創新技術博覽會 #Taiwan_Innotech_Expo
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: